[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623543":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":114,"collaborators":25,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":25,"eligibilityCriteria":123,"healthyVolunteers":120,"sex":124,"minAge":125,"maxAge":25,"enrollmentInfo":126,"targetDuration":25,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":143,"whyStopped":25,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Ulsan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stop Antiplatelet","EXPERIMENTAL","Antiplatelet discontinuation group",[13],"Drug: Stop Antiplatelet",{"label":15,"type":16,"description":17,"interventionNames":18},"Continue Antiplatelet","ACTIVE_COMPARATOR","Antiplatelet continuation group",[19],"Drug: Continue Antiplatelet",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Antiplatelet discontinuation after DCB treatment",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Antiplatelet continuation after DCB treatment",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Eun-Seok Shin, MD","CONTACT","+82-10-6319-4025","sesim1989@gmail.com",[36,50,63,75,87,96,108],{"facility":37,"status":25,"city":38,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Korea University Ansan Hospital","Ansan","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.52613,35.46836,{"lat":44,"lon":43},[47],{"name":48,"role":32,"phone":25,"phoneExt":25,"email":49},"Sunwon Kim, MD","sunwon11@hanmail.net",{"facility":51,"status":25,"city":52,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Kangwon National University Hospital","Chuncheon",{"type":41,"coordinates":54},[55,56],127.73417,37.87472,{"lat":56,"lon":55},[59],{"name":60,"role":32,"phone":61,"phoneExt":25,"email":62},"Ae-Young Her, MD","+82-10-6375-3863","hermartha@hanmail.net",{"facility":64,"status":25,"city":65,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Kosin University Hospital","Pusan",{"type":41,"coordinates":67},[68,69],128.02524,35.70128,{"lat":69,"lon":68},[72],{"name":73,"role":32,"phone":25,"phoneExt":25,"email":74},"Soo-Jin Kim, MD","circleabc@naver.com",{"facility":76,"status":25,"city":77,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Korea University Guro Hospital","Seoul",{"type":41,"coordinates":79},[80,81],126.9784,37.566,{"lat":81,"lon":80},[84],{"name":85,"role":32,"phone":25,"phoneExt":25,"email":86},"Dong Oh Kang, MD","gelly9@naver.com",{"facility":88,"status":25,"city":77,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Samsung Medical Center",{"type":41,"coordinates":90},[80,81],{"lat":81,"lon":80},[93],{"name":94,"role":32,"phone":25,"phoneExt":25,"email":95},"Joo Myung Lee, MD","drone80@hanmail.net",{"facility":97,"status":25,"city":98,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Ulsan Medical Center","Ulsan",{"type":41,"coordinates":100},[101,102],129.31667,35.53722,{"lat":102,"lon":101},[105],{"name":106,"role":32,"phone":25,"phoneExt":25,"email":107},"Chang-Bae Sohn, MD","scb77@daum.net",{"facility":5,"status":25,"city":98,"state":25,"zip":25,"country":39,"countryCode":25,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},{"type":41,"coordinates":110},[101,102],{"lat":102,"lon":101},[113],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"type":115,"investigatorFullName":116,"investigatorTitle":117,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Eun-Seok Shin","Professor","100623543","discontinuation-of-antiplatelet-therapy-after-drug-coated-balloon-treatment-100623543",false,"NCT07398001","Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment","Inclusion Criteria:\n\n1. Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.\n2. Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.\n3. Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.\n4. Patients who have not experienced major bleeding since the index DCB treatment.\n5. Patients who are receiving antiplatelet therapy at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patients with concomitant vascular disease requiring long-term antiplatelet therapy.\n2. Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.\n3. Patients who are participating in another drug or coronary device clinical study at the time of enrollment.","ALL","19 Years",{"count":127,"type":128},1042,"ESTIMATED","INTERVENTIONAL",[131],"NA","The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.\n\nThe main questions it aims to answer are:\n\nDoes stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?\n\nResearchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.\n\nParticipants will:\n\nBe randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time",[134,135,136],"Percutaneous Coronary Intervention","Antiplatelet Therapy","Drug-coated Balloon",[138,139,140,141,142],"coronary artery disease","drug-coated balloon","percutaneous coronary intervention","antiplatelet therapy","clinical outcomes","NOT_YET_RECRUITING","2026-02-02",{"date":146,"type":147},"2026-02-09","ACTUAL",{"date":149,"type":128},"2026-02-12",{"date":151,"type":128},"2030-07-31",{"name":5,"class":6},7]